Global Vascular Dementia Treatment Market to Reach USD 8.99 Billion by 2033 at a 4.77% of CAGR Amid Rising Incidence and Improved Treatment Options

Vascular Dementia Treatment Market

The global vascular dementia treatment market, valued at USD 4.65 billion in 2022, is projected to grow steadily to USD 5.64 billion by the end of 2023, reflecting a year-over-year increase of over 5%. According to industry forecasts, the market is set to expand at a compound annual growth rate (CAGR) of 4.77% between 2023 and 2033, ultimately reaching a valuation of USD 8.99 billion by FY 2033.

The rising global incidence of vascular dementia, driven by an aging population and increased awareness around early diagnosis and intervention, is a significant factor contributing to this market growth. Advances in treatment options, alongside ongoing research in neurovascular health, are expected to enhance treatment effectiveness and improve patient outcomes. Additionally, pharmaceutical companies are intensifying their efforts to develop innovative therapeutics, further supporting market expansion.

In vascular dementia, these symptoms occur when the brain is damaged because of problems with the blood supply to the brain affecting brain regions important for memory, cognition, and behavior. It declines in thinking skills, caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and number of vascular changes. A growing number of experts prefer the term “vascular cognitive impairment” (VCI) to “vascular dementia” because they feel it better expresses the concept that vascular thinking changes can range from mild to severe. According to the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline, VaD can be classified into four major subtypes: post-stroke dementia (PSD) defined as dementia manifesting within 6 months after a stroke; Subcortical ischemic vascular dementia (SIVAD); Multi-infarct (cortical) dementia; and mixed dementia.

The diagnosis of vascular dementia should be suspected in patients with significant vascular risk factors, stroke, or heart disease who exhibit abrupt changes in cognition. Brain imaging demonstrating the presence of relevant lesions of cerebrovascular disease is crucial for diagnosing vascular dementia.

Key Takeaways from the Market Study

• Market share of individual therapies with the current and forecasted 7 million market size from 2019-2032.
• Decline in thinking skills, caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients.
• Prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors, with prevention in the management of stroke, by early diagnosis and appropriate treatment of acute stroke
• No cure for the condition or a way to reverse the damage already happened. But treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.
• North America is expected to occupy a major share of the overall dementia drugs market during the forecasted period, followed by Asia where Malaysia has shown that the percentage of the population aged 65 years and over (old age) increased from 6.7% in 2019 to 7.0% in 2020.

Prominent Drivers Influencing Market Growth of Vascular Dementia Treatment

In Vascular dementia, decreased blood flow damages the brain tissue. Blood flow to brain tissue may be reduced by a partial blockage or completely blocked by a blood clot. Currently, there is no cure for the condition or a way to reverse the damage already happened. But, treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.

The progress in the understanding of vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in the development of promising symptomatic and preventive treatments. The primary prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors. This can be achieved by addressing vascular risk factors, including arterial hypertension, lipid abnormalities, atrial fibrillation, myocardial infarction, coronary heart disease, diabetes, atherosclerosis, smoking, and hyperhomocysteinemia.

Secondary prevention may include management of stroke and prevention, by early diagnosis and appropriate treatment of acute stroke; prevention of stroke recurrence; and slowing of progression of brain changes associated with VaD by intensive management of existing risk factors.

The treatment goal includes symptomatic improvement of the core symptoms such as cognition, function, and behavior; slowing of progression of disease; and treatment of neuropsychiatric symptoms such as depression, anxiety, and others.

Competitive Landscape

Some of the prominent players are-

• Charsire Biotechnology Corp
• ProNeurogen Therapeutics
• Resverlogix Corp.
• Eisai Co., Ltd.
• Novartis AG
• Cipla Inc.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd
• Dr. Reddy’s Laboratories Ltd
• Johnson & Johnson Services, Inc.

Key Companies Profiled

• BCG Matrix
• PESTLE Analysis
• SWOT Analysis
• Porter’s five forces
• Market Entry Strategies, Inc.
• Eisai Inc.
• Ever Neuro Pharma GmbH
• Geny Research Corp.
• Novartis
• Charsire Biotechnology Corp.
• LLC Merz Pharma
• Otsuka Pharmaceutical Co. Ltd.
• Johnson & Johnson Pharmaceutical Research & Development LLC.

A Full Report Overview

Key Segments Profiled in the Vascular Dementia Treatment Industry Analysis

By Type:

• Pipeline Development Activities
• Reimbursement Scenario in Vascular Dementia (VaD)
• Multi-infarct dementia
• Binswanger disease
• Vascular dementia from a strategic single-infarct
• BAC: Charsire Biotechnology Corp
• PNA1: ProNeurogen Therapeutics

By Treatment:

• Drug class
• Route of administration
• Distribution channel

By End User:

• Hospitals and Clinics
• Rehabilitation Centers
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube